

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)



(10) International Publication Number
WO 2022/099071 A1

(51) International Patent Classification:

C07D 413/14 (2006.01) C07C 255/60 (2006.01)
C07C 237/46 (2006.01) C07D 211/34 (2006.01)
C07C 255/53 (2006.01) C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2021/058334

(22) International Filing Date:

05 November 2021 (05.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/110,792 06 November 2020 (06.11.2020) US

(71) Applicant: INCYTE CORPORATION [US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors: WANG, Dengjin; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). CARPER, Daniel; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). JIA, Zhongjiang; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). SHEN, Bo; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). SCLAFANI, Joseph A.; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). WILSON, Robert; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). ZHOU, Jiacheng; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). SULEIMAN, Osama; Johnson Matthey PLC, 250 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WE (GB). WRIGHT, Mark; Johnson Matthey PLC, 250 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WE (GB).

(74) Agent: BOYLE, Craig D. et al.; P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PROCESS FOR MAKING A PD-1/PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF

(57) Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

WO 2022/099071 A1